Phaseline

Companies › Taiho Pharmaceutical

Taiho Pharmaceutical: clinical trials, targets and expected readouts

5 active drug programs in 19 registered trials: 7 Phase 1, 7 Phase 2, 4 Phase 3, 1 Phase 4; Oncology, Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Zimberelimab (AB122)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Biliary Tract Cancer; Advanced or Metastatic Solid TumorJun 2027
Imatinib
Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
ABL1, PDGFRB, KIT, BCRPhase 1Gastrointestinal Stromal Tumors; Hematological Neoplasms; Tyrosine Kinase Inhibitors; Leukemia, Acute Lymphoblastic …Dec 2026
Pimitespib
HSP90 inhibitor
HSP90AA1, HSP90AB1Phase 1Gastrointestinal Stromal TumorsDec 2026
ASTX030 (AZA + CED)
DNA methyltransferase inhibitor (azacitidine) combined with cytidine deaminase inhibitor (
DNMT1Phase 1Myelodysplastic Syndrome (MDS)Dec 2027
TAS0953/HM06
RET inhibitor
RETPhase 1RET-altered Non Small Cell Lung CancerMar 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04147533ImatinibPhase 2Chronic Myeloid Leukemia, Chronic PhaseOncologyJun 2026
NCT05277844ImatinibPhase 2Oligometastatic DiseaseOncologyNov 2026
NCT05245968PimitespibPhase 1Gastrointestinal Stromal TumorsOncologyDec 2026
NCT05245968ImatinibPhase 1Gastrointestinal Stromal TumorsOncologyDec 2026
NCT03844360ImatinibPhase 4Hematological NeoplasmsOncologyDec 2026
NCT05009927ImatinibPhase 2Metastatic Gastrointestinal Stromal Tumor (GIST)OncologyJan 2027
NCT00044304ImatinibPhase 2Eosinophilic Myeloid NeoplasmOncologyMar 2027
NCT04999761Zimberelimab (AB122)Phase 1Advanced or Metastatic Solid TumorOncologyJun 2027
NCT05493215ImatinibPhase 2Gastrointestinal Stromal TumorsOncologyDec 2027
NCT04608110ASTX030 (AZA + CED)Phase 1Myelodysplastic Syndrome (MDS)HematologyDec 2027
NCT06962254ImatinibPhase 1Solid Tumor CancerOncologyMar 2028
NCT05753384ImatinibPhase 3Tyrosine Kinase InhibitorsOncologyDec 2028
NCT04933669ImatinibPhase 2Progression-free SurvivalOncologyDec 2029
NCT04683250TAS0953/HM06Phase 1RET-altered Non Small Cell Lung CancerOncologyMar 2030
NCT07710885Zimberelimab (AB122)Phase 3Biliary Tract CancerOncologyApr 2030
NCT07171203ImatinibPhase 1Gastrointestinal Stromal TumorsOncologyJul 2030
NCT04307576ImatinibPhase 3Leukemia, Acute LymphoblasticOncologyJun 2033
NCT02413736ImatinibPhase 3SarcomaOncologyJun 2033
NCT06119789ImatinibPhase 2Rare Malignant NeoplasmOncologyNov 2033

Targets

RET (1) HSP90AA1 (1) HSP90AB1 (1) ABL1 (1) PDGFRB (1) KIT (1) BCR (1) DNMT1 (1) PDCD1 (1)

Companies with the same targets

Roche Chia Tai Tianqing Pharmaceutical Group Novartis Daiichi Sankyo Blueprint Medicines Eli Lilly Bayer Gossamer Bio USA Etnova Therapeutics Advenchen Laboratories

Companies built like this

Nanjing Sanhome Pharmaceutical TORL Biotherapeutics Shandong Boan Biotechnology Taiho Oncology Chengdu New Radiomedicine Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.